Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) Analysis, Size, Share, Trends, & Forecast from 2020-2026
REPORT HIGHLIGHT
Thalassemia market was valued at USD 2.48 billion by 2019, growing with 9.7% CAGR during the forecast period, 2020-2026.
Thalassemia is an inherited or genetic blood disorder, which is characterized by the abnormal production of hemoglobin present in the blood cells of the human body. Hemoglobin is the protein that functions to carry oxygen all through the human body, which results in the annihilation of the blood cells leading to anemia.
Market Dynamics
The increasing population, growing demand for enhanced curative gene therapies, and rising awareness regarding available treatment options are the major factors boosting the growth of the global thalassemia market. According to the World Health Organization (WHO), approximately 4.4 every 10,000 live births are affected by thalassemia all across the globe. And, about 5% of the total world population has a variation in the beta or alpha part of the hemoglobin molecule. Furthermore, a surge in the development of pipeline drugs and novel therapies coupled with research & development is another factor propelling the market growth. However, high costs and the lack of viable treatment options associated with the disease are predicted to restrict the market growth in the coming future. On the contrary, the growing investments in healthcare by governments and various key players are expected to create lucrative growth opportunities in the overall market during the forecast period.
Thalassemia Type Takeaway
“Alpha thalassemia segment to witness the fastest growth during the forecast period”
Based on the thalassemia type, the global market is bifurcated into alpha-thalassemia and beta-thalassemia. Of these, the alpha thalassemia segment is estimated to grow at the fastest rate during the forecast period mainly because it is one of the most common autosomal disorders. The growing prevalence of alpha-globin disorders in the U.S. and other western countries is impelling the segmental market growth. In addition, the prevalence of alpha thalassemia is more as compared to the beta-thalassemia, which will fuel the growth of the alpha-thalassemia segment during the forecast period. On the other hand, the beta-thalassemia segment is projected to witness significant growth during the period of forecast. According to the WHO, around 1.5% of the worldwide population is affected by beta-thalassemia.
Therapeutic Class Takeaway
“Blood transfusion segment is anticipated to dominate the industry by 2026”
On the basis of therapeutic class, the overall market for thalassemia is categorized into iron chelating drugs, blood transfusion, folic acid supplements, and gene therapy. The iron-chelating drugs and the gene therapy segment are further sub-categorized into exjade/jadenu (deferasirox) and lentiglobin respectively. Among these, the blood transfusion segment accounted for the largest market share in 2019 and is expected to dominate the industry during the forecast period. This dominance is majorly attributed to the low risk involved in blood transfusion treatment due to careful blood screening. In addition, this treatment has a high success rate compared to other treatments, which makes it most preferable by patients. This will contribute to the segmental market growth in the projected timeframe.
On the other hand, the gene therapy segment is estimated to grow at a considerable rate during the forecast period as it has the potential to change the thalassemia treatment landscape amidst regulatory uncertainties and major clinical development challenges. In addition, scientists are involved in investigating several genetic techniques for the treatment of thalassemia.
Pipeline Products Takeaway
Gene therapy is considered to be the forefront of emerging curative therapies for thalassemia condition, with several genomic molecules under late stage clinical studies. Some of the key players’ have already initiative phase III trials for this condition while many are in preclinical evaluation. Recently, a new approach of gene editing for the correction of beta-globin mutation or disruption of the BCL11A gene has been initiated to increase fetal hemoglobin production. This molecule is expected to achieve the preclinical stage soon.
Furthermore, gene correction of autologous hematopoietic stem cells using Lentiviral vectors has been successfully established with a projected launch in the market by 2022. Even though curative possibilities for this disease is expanding, making it accessible to a larger number of patients on a global level remains a challenge.
End Use Takeaway
“Hospital segment to be most lucrative in the forecast period”
Based on end-use, the worldwide thalassemia market is classified into a hospital, research institute, laboratories, and clinics. Among these, the hospital segment accounted for the majority of share in the market in 2009 and is projected to lead the market during the forecast period. This is primarily owing to growth in the number of admissions in hospitals for thalassemia treatment. In addition, the growing prevalence of thalassemia is also likely to drive the segmental market growth. On the other hand, the laboratories segment is expected to hold a significant share in the market throughout the forecast owing to growing awareness amongst people regarding thalassemia treatment.
Regional Takeaway
“North America region to hold a significant market share by 2026”
Depending on the region, the global industry is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America thalassemia market held the highest market share in 2019 and is expected to grow at a significant rate during the period of forecast. This is majorly owing to increasing awareness of thalassemia and the rising incidence of alpha thalassemia in this region.
Moreover, the increased effort by the government in various countries of the North America region to support gene therapy is another responsible for the regional market growth. On the other hand, the Asia Pacific market for thalassemia is expected to grow at the fastest CAGR owing to increasing investments by governments in healthcare infrastructure.
COVID-19 Impact
The worldwide spread of COVID-19 disease has adversely affected the global thalassemia market. Multiple challenges are being faced by the market such as unavailability of blood in blood banks, transfusion facilities, and transportation for the treatment of thalassemia disorders. Moreover, the overall market is likely to recover at a slow rate post the COVID-19 pandemic.
Key Vendor Takeaway
The leading players of the global thalassemia market include Bluebird Bio, ApoPharmaInc, Sangamo Bioscience, Bellicum Pharmaceuticals, Pfizer, Inc., AcceleronPharma / Celgene Corporation, Novartis, KiadisPharma. These players are involved in R&D activities to develop an improved treatment for thalassemia to hold a strong position in the global industry. Companies are involved in developing new products for the disease treatment. For instance, recently, in January 2020, Bluebird Bio launched its first beta thalassemia gene therapy namely, ‘Zynteglo’ in Germany. A German manufacturer, apceth Biopharma is recruited by the company to produce Zynteglo.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2015 to2018
- Base Year – 2019
- Estimated Year – 2020
- Projected Year – 2026
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLBOAL THALASSEMIA MARKET KEY PLAYERS
- AcceleronPharma / Celgene Corporation
- Novartis AG
- Bluebird Bio
- ApoPharmaInc
- Sangamo Bioscience
- Bellicum Pharmaceuticals
- Pfizer, Inc.
- KiadisPharma
GLBOAL THALASSEMIA MARKET, BY THALASSEMIA TYPE
- Alpha Thalassemia
- Beta Thalassemia
GLBOAL THALASSEMIA MARKET, BY THERAPEUTIC CLASS
- Gene Therapy
- LentiGlobin
- Iron Chelating Drugs
- Exjade/Jadenu (deferasirox)
- Blood Transfusions
- Folic Acid Supplements
GLBOAL THALASSEMIA MARKET, BY END-USE
- Research Institutes
- Hospital
- Laboratories
- Clinics
- Others
GLOBAL THALASSEMIA MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Singapore
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. THALASSEMIA MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Thalassemia Type
2.1.2. Market Snippet by Therapeutic Class
2.1.3. Market Snippet by End Use
2.1.4. Market Snippet by Region
2.2. Competitive Insights
3. THALASSEMIA KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. THALASSEMIA INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
4.5. COVID-19 Impact Analysis
4.5.1. Pre-COVID-19 Impact Analysis
4.5.2. Post-COVID-19 Impact Analysis
5. THALASSEMIA MARKET LANDSCAPE
5.1. Market Share Analysis
5.2. Key Innovators
5.3. Breakdown Data, by Key manufacturer
5.3.1. Established Player Analysis
5.3.2. Emerging Player Analysis
6. THALASSEMIA MARKET – BY THALASSEMIA TYPE
6.1. Overview
6.1.1. Segment Share Analysis, By Thalassemia Type, 2019 & 2026 (%)
6.2. Alpha Thalassemia
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3. Beta Thalassemia
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7. THALASSEMIA MARKET – BY THERAPEUTIC CLASS
7.1. Overview
7.1.1. Segment Share Analysis, By Thalassemia Type, 2019 & 2026 (%)
7.2. Gene Therapy
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.2.2.1. LentiGlobin
7.2.2.1.1. Overview
7.2.2.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.3. Iron Chelating Drugs
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.3.2.1. Exjade/Jadenu (deferasirox)
7.3.2.1.1. Overview
7.3.2.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.4. Blood Transfusions
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.5. Folic Acid Supplements
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8. THALASSEMIA MARKET – BY END USE
8.1. Overview
8.1.1. Segment Share Analysis, By End Use, 2019 & 2026 (%)
8.2. Hospital
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8.3. Laboratories
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8.4. Research Institutes
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8.5. Clinics
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9. THALASSEMIA MARKET– BY GEOGRAPHY
9.1. Introduction
9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
9.2. North America
9.2.1. Overview
9.2.2. Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.2.4. North America Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US$ Million)
9.2.5. North America Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US$ Million)
9.2.6. North America Market Size and Forecast, By End Use, 2015 – 2026 (US$ Million)
9.2.7. U.S.
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.2.8. Canada
9.2.8.1. Overview
9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US$ Million)
9.3.6. Europe Market Size and Forecast, By End Use, 2015 – 2026 (US$ Million)
9.3.7. Germany
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.8. Italy
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.9. United Kingdom
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.10. France
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.11. Rest of Europe
9.3.11.1. Overview
9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US$ Million)
9.4.6. Asia Pacific Market Size and Forecast, By End Use, 2015 – 2026 (US$ Million)
9.4.7. India
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.8. China
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.9. Japan
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.10. South Korea
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.11. Rest of APAC
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US$ Million)
9.5.5. Latin America Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US$ Million)
9.5.6. Latin America Market Size and Forecast, By End Use, 2015 – 2026 (US$ Million)
9.5.7. Brazil
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5.8. Mexico
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5.9. Argentina
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US$ Million)
9.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2015 – 2026 (US$ Million)
9.6.7. Saudi Arabia
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.6.8. United Arab Emirates
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
10. KEY VENDOR ANALYSIS
10.1. Bluebird Bio
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Thalassemia Type Benchmarking
10.1.4. Strategic Initiatives
10.2. ApoPharmaInc
10.3. Sangamo Bioscienc
10.4. Bellicum Pharmaceuticals
10.5. Pfizer, Inc.
10.6. AcceleronPharma / Celgene Corporation
10.7. Novartis AG
10.8. KiadisPharma
11. 360 DEGREE ANALYSTVIEW
12. APPENDIX
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
List of Tables
TABLE List of data sources
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Thalassemia market: End Usenapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Thalassemia Type
TABLE Global Thalassemia market, by Thalassemia Type 2015-2026 (USD Million)
TABLE Thalassemia market: Therapeutic Class Snapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class
TABLE Global Thalassemia market, by Therapeutic Class 2015-2026 (USD Million)
TABLE Thalassemia market: End UseSnapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by End Use
TABLE Global Thalassemia market, by End Use2015-2026 (USD Million)
TABLE Thalassemia market: Regional Snapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global Thalassemia market, by Region 2015-2026 (USD Million)
TABLE North America Thalassemia market, by Country, 2015-2026 (USD Million)
TABLE North America Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
TABLE North America Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
TABLE North America Thalassemia market, by End Use, 2015-2026 (USD Million)
TABLE Europe Thalassemia market, by Country, 2015-2026 (USD Million)
TABLE Europe Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
TABLE Europe Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
TABLE Europe Thalassemia market, by End Use, 2015-2026 (USD Million)
TABLE Asia Pacific Thalassemia market, by Country, 2015-2026 (USD Million)
TABLE Asia Pacific Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
TABLEAsia Pacific Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
TABLE Asia Pacific Thalassemia market, by End Use, 2015-2026 (USD Million)
TABLE Latin America Thalassemia market, by Country, 2015-2026 (USD Million)
TABLE Latin America Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
TABLE Latin America Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
TABLE Latin America Thalassemia market, by End Use, 2015-2026 (USD Million)
TABLE Middle East and Africa Thalassemia market, by Country, 2015-2026 (USD Million)
TABLE Middle East and Africa Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
TABLE Middle East and Africa Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
TABLE Middle East and Africa Thalassemia market, by Distribtion Channel, 2015-2026 (USD Million)
List of Figures
FIGURE Thalassemia market segmentation
FIGURE Market Research Methodology
FIGURE Value chain analysis
FIGURE Porter’s Five Forces Analysis
FIGURE Market Attractiveness Analysis
FIGURE COVID-19 Impact Analysis
FIGURE Pre & Post COVID-19 Impact Comparision Study
FIGURE Competitive Landscape; Key company market share analysis, 2018
FIGURE Thalassemia Type segment market share analysis, 2019 & 2026
FIGURE Thalassemia Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Alpha Thalassemia market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Beta Thalassemia market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Therapeutic Class segment market share analysis, 2019 & 2026
FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Iron Chelating Drugs market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Exjade/Jadenu (deferasirox) market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Blood Transfusions market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Folic Acid Supplements market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Gene Therapy market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE LentiGlobin market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE End Use segment market share analysis, 2019 & 2026
FIGURE End Use segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Hospital market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Laboratories market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Research Institutes market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Clinics market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Regional segment market share analysis, 2019 & 2026
FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE North America Thalassemia market share and leading players, 2018
FIGURE Europe Thalassemia market share and leading players, 2018
FIGURE Asia Pacific Thalassemia market share and leading players, 2018
FIGURE Latin America Thalassemia market share and leading players, 2018
FIGURE Middle East and Africa Thalassemia market share and leading players, 2018
FIGURE North America Thalassemia market share analysis by country, 2018
FIGURE U.S. Thalassemia Market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Canada Thalassemia Market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Europe Thalassemia Market share analysis by country, 2018
FIGURE Germany Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Spain Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Italy Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE UK Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE FranceThalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Rest of the Europe Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Asia Pacific Thalassemia market share analysis by country, 2018
FIGURE India Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE China Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Japan Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE South Korea Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Singapore Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Rest of APACThalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Latin America Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Latin AmericaThalassemia market share analysis by country, 2018
FIGURE Brazil Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Mexico Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Argentina Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Rest of LATAM Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Middle East and Africa Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Middle East and Africa Thalassemia market share analysis by country, 2018
FIGURE Saudi Arabia Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE United Arab Emirates Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
